<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">radhyd</journal-id><journal-title-group><journal-title xml:lang="ru">Радиационная гигиена</journal-title><trans-title-group xml:lang="en"><trans-title>Radiatsionnaya Gygiena = Radiation Hygiene</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1998-426X</issn><issn pub-type="epub">2409-9082</issn><publisher><publisher-name>NIIRG</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21514/1998-426X-2023-16-1-32-39</article-id><article-id custom-type="elpub" pub-id-type="custom">radhyd-932</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Научные статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Scientific articles</subject></subj-group></article-categories><title-group><article-title>Исследование радиопротекторных свойств фумаровой кислоты и фумарата 3-оксипиридина при действии ионизирующего излучения на клетки человека</article-title><trans-title-group xml:lang="en"><trans-title>Study of the radioprotective properties of fumaric acid and 3-hydroxypyridine fumarate under the action of ionizing radiation on human cells</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Купцова</surname><given-names>П. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuptsova</surname><given-names>P. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Купцова Полина Сергеевна – преподаватель отделения биотехнологий; младший научный сотрудник</p><p>249039, Калужская область, городской округ «Город Обнинск», город Обнинск, тер. Студгородок, д. 1</p></bio><bio xml:lang="en"><p>Polina S. Kuptsova – Lecturer in the Department of Biotechnology; Junior Researcher</p><p>Obninsk</p></bio><email xlink:type="simple">kuptsova_apollinaria@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Комарова</surname><given-names>Л. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Komarova</surname><given-names>L. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Комарова Людмила Николаевна – доктор биологических наук, профессор, заведующая кафедрой биологии</p><p>Обнинск</p></bio><bio xml:lang="en"><p>Luidmila N. Komarova – Doctor of Biological Sciences, Professor, Head of the Department of Biology</p><p>Obninsk</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Выпова</surname><given-names>Е. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Vypova</surname><given-names>E. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Выпова Елена Романовна – заведующая учебно-научной лабораторией биологии</p><p>Обнинск</p></bio><bio xml:lang="en"><p>Elena R. Vypova – Head of Educational and Scientific Laboratory of Biology</p><p>Obninsk</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Обнинский институт атомной энергетики — филиал Национального исследовательского ядерного университета «МИФИ»; Медицинский радиологический научный центр им. А.Ф. Цыба – филиал Национального медицинского исследовательского центра радиологии Министерства здравоохранения России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Obninsk Institute for Nuclear Power Engineering; A. Tsyb National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Обнинский институт атомной энергетики — филиал Национального исследовательского ядерного университета «МИФИ»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Obninsk Institute for Nuclear Power Engineering</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>04</day><month>04</month><year>2023</year></pub-date><volume>16</volume><issue>1</issue><fpage>32</fpage><lpage>39</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Купцова П.С., Комарова Л.Н., Выпова Е.Р., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Купцова П.С., Комарова Л.Н., Выпова Е.Р.</copyright-holder><copyright-holder xml:lang="en">Kuptsova P.S., Komarova L.N., Vypova E.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.radhyg.ru/jour/article/view/932">https://www.radhyg.ru/jour/article/view/932</self-uri><abstract><p>В современном мире сложилась такая обстановка, что развитие ядерной энергетики и применение источников ионизирующих излучений в различных сферах деятельности создали потенциальную угрозу радиационной опасности для человека. В связи с этим актуальным направлением является изучение способов повышения радиорезистентности клеток и тканей человека к действию ионизирующего излучения. Кроме того, радиозащитные соединения имеют важное значение и в лучевой терапии, поскольку нормальные ткани пациентов должны быть защищены от лучевого поражения при использовании высоких доз облучения при лечении злокачественных новообразований. Однако радиопротекторы, применяемые в настоящее время, обладают некоторыми недостатками. Цель работы – исследование радиопротекторных свойств фумаровой кислоты и фумарата 3-оксипиридина при действии гамма-излучения и излучения ионов 12С на опухолевые (нейробластома SK-N-BE) и нормальные (фибробласты hTERT) клетки человека. Действие излучения оценивалось по критериям выживаемости клеток в культуре, времени удвоения и клоногенной активности. Показано, что применение фумаровой кислоты и фумарата 3-оксипиридина оказывает радиозащитное действие на нормальные и опухолевые клетки при облучении их гамма-излучением в дозах 1, 4, 6 и 10 Гр. Применение фумаровой кислоты и фумарата 3-оксипиридина не оказывает радиозащитное действие на опухолевые клетки при облучении их ионами 12С. Сравнительный анализ результатов действия препаратов при облучении гамма-квантами и ионами 12С показал существенную зависимость проявления модифицирующих свойств от качества излучения. Исследование времени удвоения клеток показало, что присутствие в контроле препаратов не увеличивало данный показатель. Напротив, при действии гамма-излучения в дозе 10 Гр препараты снижали время удвоения фибробластов более чем в 2 раза и время удвоения клеток нейробластомы почти в 1,5 раза. Полученные данные говорят о том, что антиоксидантные свойства изученных препаратов открывают новые возможности модификации действия ионизирующего излучения при терапии онкологических заболеваний. Применение фумаровой кислоты и фумарата 3-оксипиридина позволит уменьшить лучевую нагрузку на здоровые клетки, в том числе снизить действие вторичных продуктов на здоровые клетки за пиком Брэгга при действии ионно-углеродной терапии.</p></abstract><trans-abstract xml:lang="en"><p>In the modern world, such a situation has developed that the development of nuclear energy and the use of sources of ionizing radiation in various fields of activity have created a potential threat of radiation hazard to humans. In this connection, the actual direction is the study of ways to increase the radioresistance of human cells and tissues to the action of ionizing radiation. In addition, radioprotective compounds are also important in radiotherapy, since normal tissues of patients must be protected from radiation damage when using high doses of radiation in the treatment of malignant neoplasms. However, the radioprotectors currently used have some disadvantages. The aim of this work is to study the radioprotective properties of fumaric acid and 3-hydroxypyridine fumarate under the action of gamma radiation and radiation of 12C ions on tumor (SK-N-BE neuroblastoma) and normal (hTERT fibroblasts) human cells. The effect of radiation was evaluated according to the criteria of cell survival in culture, doubling time and clonogenic activity. It has been shown that the use of fumaric acid and 3-hydroxypyridine fumarate has a radioprotective effect on normal and tumor cells when they are irradiated with gamma radiation at doses of 1, 4, 6 and 10 Gy. The use of fumaric acid and 3-hydroxypyridine fumarate does not have a radioprotective effect on tumor cells when they are irradiated with 12C ions. A comparative analysis of the results of the action of the preparations with gamma rays and 12C ions showed a significant dependence of the manifestation of modifying properties on the quality of radiation. The study of cell doubling time showed that the presence of drugs in the control did not increase this indicator. On the contrary, under the action of gamma radiation at a dose of 10 Gy, the preparations reduced the doubling time of fibroblasts by more than two times and the doubling time of neuroblastoma cells by almost 1.5 times. The data obtained indicate that the antioxidant properties of the studied preparations open up new possibilities for modifying the action of ionizing radiation in the treatment of oncological diseases. The use of fumaric acid and 3-hydroxypyridine fumarate will reduce the radiation load on healthy cells, including reducing the effect of secondary products on healthy cells beyond the Bragg peak under the action of carbon ion therapy.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>радиопротекторы</kwd><kwd>гамма-излучение</kwd><kwd>ионы 12С</kwd><kwd>фибробласты</kwd><kwd>нейробластома</kwd><kwd>выживаемость</kwd><kwd>клоногенный анализ</kwd><kwd>время удвоения</kwd><kwd>фумаровая кислота</kwd><kwd>фумарат 3-оксипиридина</kwd></kwd-group><kwd-group xml:lang="en"><kwd>radioprotectors</kwd><kwd>gamma radiation</kwd><kwd>12С ions</kwd><kwd>fibroblasts</kwd><kwd>neuroblastoma</kwd><kwd>survival</kwd><kwd>clonogenic analysis</kwd><kwd>doubling time</kwd><kwd>fumaric acid</kwd><kwd>3-oxypyridine fumarate</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ferlay J., Colombet M., Soerjomataram I., et al. Cancer statistics for the year 2020: An overview // International Journal of Cancer. 2021. Vol. 149, No. 4. P. 778–789. DOI:10.1002/ijc.33588.</mixed-citation><mixed-citation xml:lang="en">Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. International Journal of Cancer. 2021;149(4):778–789. – Available from: https://onlinelibrary.wiley.com/doi/10.1002/ijc.33588. DOI:10.1002/ijc.33588. [Accessed 5 Jul 2022].</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 252 с.</mixed-citation><mixed-citation xml:lang="en">Kaprin AD, Starinsky VV, Shahzadova AO Malignant neoplasms in Russia in 2020 (morbidity and mortality). Мoscow: National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation; 2021. 252 p. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Abshire D., Lang, M.K. The Evolution of Radiation Therapy in Treating Cancer // Seminars in oncology nursing. 2018. Vol. 34, No. 2. P. 151–157. DOI:10.1016/j.soncn.2018.03.006.</mixed-citation><mixed-citation xml:lang="en">Abshire D, Lang MK. The Evolution of Radiation Therapy in Treating Cancer. Seminars in Oncology Nursing. 2018;34(2):151-157. – Available from: https://www.sciencedirect.com/science/article/abs/pii/S0749208118300196?via%3Dihub. DOI:10.1016/j.soncn.2018.03.006. [Accessed 13 Mar 2022].</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ben Barak A., Golan H., Waldman D., Arkovitz M.S. Surgical Treatment of Neuroblastoma // The Israel Medical Association journal: IMAJ. 2017. Vol. 19, No. 11, P. 691–695.</mixed-citation><mixed-citation xml:lang="en">Ben Barak A, Golan H, Waldman D, Arkovitz MS. Surgical Treatment of Neuroblastoma. Israel Medical Association Journal. 2017 v;19(11):691-695. – Available from: https://www.ima.org.il/MedicineIMAJ/viewarticle.aspx?year=2017&amp;month=11&amp;page=691.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Wang H., Mao X. Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer // Drug design, development and therapy. 2020. Vol. 14. P. 2423-2433. DOI: 10.2147/DDDT.S253961.</mixed-citation><mixed-citation xml:lang="en">Wang H, Mao X. Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer. Drug Design, Development and Therapy. 2020;14:2423-2433 – Available from: https://www.dovepress.com/evaluation-of-the-efficacy-of-neoadjuvantchemotherapy-for-breast-canc-peer-reviewed-fulltext-article-DDDT. DOI: 10.2147/DDDT.S253961. [Accessed 18 Jun 2022].</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Thomas R., Al-Khadairi G., Roelands J., et al. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives // Frontiers in immunology. 2018. Vol. 9. DOI:10.3389/fimmu.2018.00947.</mixed-citation><mixed-citation xml:lang="en">Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, et al. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. Frontiers in Immunology 2018 1;9:947. 2433 – Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941317/. DOI:10.3389/fimmu.2018.00947. [Accessed 1 May 2022].</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Li H., Liu Y., Wang Y., et al. Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review) // Oncology reports. 2021. Vol. 46, No. 4. DOI:10.3892/or.2021.8174.</mixed-citation><mixed-citation xml:lang="en">Li H, Liu Y, Wang Y, Zhao X, Qi X. Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review). Oncology Reports. 2021;46(4):223. 2433 – Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424487/. DOI:10.3892/or.2021.8174. [Accessed 26 Aug 2022].</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lee Y.T., Tan Y.J., Oon C.E. Molecular targeted therapy: Treating cancer with specificity // European journal of pharmacology. 2018. Vol. 834. P. 188–196. DOI:10.1016/j.ejphar.2018.07.034.</mixed-citation><mixed-citation xml:lang="en">Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: Treating cancer with specificity. European Journal of Pharmacology. 2018 5;834:188-196. – Available from: https://www.sciencedirect.com/science/article/abs/pii/S0014299918304011?via%3Dihub. DOI:10.1016/j.ejphar.2018.07.034. [Accessed 20 Jul 2022].</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Lange C., Bednarski P.J. Photosensitizers for Photodynamic Therapy: Photochemistry in the Service of Oncology // Current pharmaceutical design. 2016. Vol. 22, No. 46. P. 6956–6974. DOI:10.2174/1381612822666161124155344.</mixed-citation><mixed-citation xml:lang="en">Lange C, Bednarski PJ. Photosensitizers for Photodynamic Therapy: Photochemistry in the Service of Oncology. Current Pharmaceutical Design. 2016;22(46):6956-6974. DOI:10.2174/1381612822666161124155344.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wang K., Tepper J.E. Radiation therapy-associated toxicity: Etiology, management, and prevention // CA: a cancer journal for clinicians. 2021. Vol. 71, No. 5. P. 437–454. DOI: 10.3322/caac.21689.</mixed-citation><mixed-citation xml:lang="en">Wang K, Tepper JE. Radiation therapy-associated toxicity: Etiology, management, and prevention. A Cancer Journal for Clinicians. 2021;71(5):437-454. – Available from: https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac. DOI: 10.3322/caac.21689. [Accessed 3 Oct 2022].</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Gardner S.J., Kim J., Chetty I.J. Modern Radiation Therapy Planning and Delivery // Hematology/Oncology Clinics of North America. 2019. Vol. 33, No. 6. P. 947-962. DOI:10.1016/j.hoc.2019.08.005.</mixed-citation><mixed-citation xml:lang="en">Gardner SJ, Kim J, Chetty IJ. Modern Radiation Therapy Planning and Delivery. Hematology/oncology clinics of North America. 2019;33(6):947-962. – Available from: https://www.sciencedirect.com/science/article/abs/pii/S088985881930098X?via%3Dihub. DOI:10.1016/j.hoc.2019.08.005. [Accessed 10 Sep 2021].</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Hwang E.J., Gorayski P., Le H., et al. Particle therapy tumour outcomes: An updated systematic review // Journal of medical imaging and radiation oncology. 2020. Vol. 64, No. 5. P. 711–724. DOI:10.1111/1754-9485.13021.</mixed-citation><mixed-citation xml:lang="en">Hwang EJ, Gorayski P, Le H, Hanna GG, Kenny L, Penniment M, et al. Particle therapy tumour outcomes: An updated systematic review. Journal of Medical Imaging and Radiation Oncology 2020;64(5):711-724. DOI:10.1111/1754-9485.13021.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Aricò G., Gehrke T., Gallas R., et al. Investigation of single carbon ion fragmentation in water and PMMA for hadron therapy // Physics in medicine and biology. 2019. Vol. 64, No. 5. DOI:10.1088/1361-6560/aafa46.</mixed-citation><mixed-citation xml:lang="en">Aricò G, Gehrke T, Gallas R, Mairani A, Jäkel O, Martišíková M. Investigation of single carbon ion fragmentation in water and PMMA for hadron therapy. Physics in Medicine and Biology. 2019 7;64(5):055018. – Available from: https://iopscience.iop.org/article/10.1088/1361-6560/aafa46. DOI:10.1088/1361-6560/aafa46. [Accessed 1 Oct 2021].</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson D., Chen Y., Ahmad S. Dose and linear energy transfer distributions of primary and secondary particles in carbon ion radiation therapy: A Monte Carlo simulation study in water // Journal of medical physics. 2015. Vol. 40, No. 4. P. 214–219. DOI:10.4103/0971-6203.170785.</mixed-citation><mixed-citation xml:lang="en">Johnson D, Chen Y, Ahmad S. Dose and linear energy transfer distributions of primary and secondary particles in carbon ion radiation therapy: A Monte Carlo simulation study in water. Journal of Medical Physics. 2015;40(4):214-9. – Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728892/. DOI:10.4103/0971-6203.170785. [Accessed 11 Oct 2022].</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Aliper A.M., Bozdaganyan M.E., Sarkisova V.A., et al. Radioprotectors.org: an open database of known and predicted radioprotectors // Aging. 2020. Vol. 12, No. 15. P. 15741–15755. DOI:10.18632/aging.103815.</mixed-citation><mixed-citation xml:lang="en">Aliper AM, Bozdaganyan ME, Sarkisova VA, Veviorsky AP, Ozerov IV, Orekhov PS, et al. Radioprotectors.org: an open database of known and predicted radioprotectors. Aging (Albany NY). 2020 15;12(15):15741-15755. – Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467366/. DOI:10.18632/aging.103815. [Accessed 11 Oct 2022].</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Mun G.I., Kim S., Choi E., et al. Pharmacology of natural radioprotectors // Archives of Pharmacal Research. 2018. Vol. 41, No. 11. P. 1033-1050. DOI:10.1007/s12272-018-1083-6.</mixed-citation><mixed-citation xml:lang="en">Mun GI, Kim S, Choi E, Kim CS, Lee YS. Pharmacology of natural radioprotectors. Archives of Pharmacal Research. 2018;41(11):1033-1050. – Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224001/. DOI:10.1007/s12272-018-1083-6</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Mishra K., Alsbeih G. Appraisal of biochemical classes of radioprotectors: evidence, current status and guidelines for future development // 3 Biotech. 2017. Vol. 7, No. 5. DOI: 10.1007/s13205-017-0925-0.</mixed-citation><mixed-citation xml:lang="en">Mishra K, Alsbeih G. Appraisal of biochemical classes of radioprotectors: evidence, current status and guidelines for future development. Biotech. 2017;7(5):292. – Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574734/. DOI: 10.1007/s13205-017-0925-0. [Accessed 12 Oct 2022].</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Бутомо Н.В., Гребенюк А.Н., Легеза В.И., и др. Основы медицинской радиобиологии. Под общ. Ред. Ушакова И.Б. СПб., изд. «Фолиант», 2004. 380 с.</mixed-citation><mixed-citation xml:lang="en">Butomo NV, Grebenjuk AN, Legeza VI, et al. Fundamentals of medical radiobiology. Saint Petersburg, «Foliant»; 2004. 380 p. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ilica R.A., Kloetzer L., Galaction A.I., Caşcaval D. Fumaric acid: production and separation // Biotechnology letters. 2019. Vol. 41, No. 1. P. 47–57. DOI:10.1007/s10529-018-2628-y.</mixed-citation><mixed-citation xml:lang="en">Ilica RA, Kloetzer L, Galaction AI, Caşcaval D. Fumaric acid: production and separation. Biotechnology Letters. 2019;41(1):47-57. DOI:10.1007/s10529-018-2628-y.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Wipke B.T., Hoepner R., Strassburger-Krogias K., et al. Different Fumaric Acid Esters Elicit Distinct Pharmacologic Responses // Neurology(R) neuroimmunology &amp; neuroinflammation. 2021. Vol. 8, No. 2. DOI:10.1212/NXI.0000000000000950.</mixed-citation><mixed-citation xml:lang="en">Wipke BT, Hoepner R, Strassburger-Krogias K, Thomas AM, Gianni D, Szak S, et al. Different fumaric acid esters elicit distinct pharmacologic responses. Neurology Neuroimmunology &amp; Neuroinflammation. 2021;19;8(2):e950. – Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862084/. DOI:10.1212/NXI.0000000000000950. [Accessed 21 May 2022].</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Volc-Platzer B. Fumaric acid esters for paediatric psoriasis // The British journal of dermatology. 2021. Vol. 185, No. 1. P. 5–6. DOI: 10.1111/bjd.20057.</mixed-citation><mixed-citation xml:lang="en">Volc-Platzer B. Fumaric acid esters for paediatric psoriasis. British Journal of Dermatology. 2021;185(1):5-6. DOI: 10.1111/bjd.20057.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Коршунова А.Б., Костычев Н.А., Инчина В.И., Чаиркин И.Н. Перспективы фармакологической коррекции острой ишемии головного мозга // Известия Самарского научного центра Российской академии наук. 2009. Т. 11, № 1. С. 1287-1290.</mixed-citation><mixed-citation xml:lang="en">Korshunova AB, Kostychev NA, Inchina VI, Chairkin IN. Prospects for pharmacological correction of acute cerebral ischemia. Izvestia of Samara Scientific Center of the Russian Academy of Sciences. 2009;11(1):1287-1290. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Сайт «Соль 2-этил-6-метил-3-гидроксипиридина с фумаровой кислотой, обладающая метаболической и кардиопротекторной активностью, и способ ее получения». URL: https://patents.google.com/patent/RU2365582C1/ru (Дата обращения: 11.11.2022).</mixed-citation><mixed-citation xml:lang="en">Site Salt of 2-ethyl-6-methyl-3-hydroxypyridine with fumaric acid with metabolic and cardioprotective activity, and method for its production: Available from: https://patents.google.com/patent/RU2365582C1/ru. [Accessed Nov 11 2022]. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Прилепский А.Ю., Дроздов А.С., Богатырев В.А., Староверов С.А. Методы работы с клеточными культурами и определение токсичности наноматериалов. СПб: Университет ИТМО, 2019. 43 с.</mixed-citation><mixed-citation xml:lang="en">Prilepsky AYu., Drozdov AS, Bogatyrev VA, Staroverov SA. Methods of working with cell cultures and determination of toxicity of nanomaterials. Saint Petersburg: ITMO University, 2019. 43 p. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Уланова Т.В., Инчина В.И., Русейкин Н.С. и др. Исследование влияния новых производных 3-гидроксипиридина и препаратов сравнения на выживаемость и некоторые биохимические показатели крови белых крыс при экспериментальном диабете // Вестник Мордовского университета. 2016. Т. 26, № 2. С. 180-191.</mixed-citation><mixed-citation xml:lang="en">Ulanova TV, Inchina VI, Rusejkin NS, Hudojkina SV, Romanova JeV. Investigation of the effect of new 3-hydroxypyridine derivatives and comparators on survival and some biochemical blood parameters of white rats in experimental diabetes. Mordovia University Bulletin. 2016;26(2):180-191. – Available from: https://cyberleninka.ru/article/n/issledovanie-vliyaniya-novyh-proizvodnyh-3-gidroksipiridina-i-preparatovsravneniya-na-vyzhivaemost-i-nekotorye-biohimicheskie. [Accessed 14 Oct 2022]. (In Russian).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
